# Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

> **NCT00143247** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 173 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Exubera® (inhaled insulin)

## Key facts

- **NCT ID:** NCT00143247
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 173 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2010-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143247, "Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00143247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*